Ernexa Therapeutics Inc.

NasdaqCM:ERNA Stock Report

Market Cap: US$14.3m

Ernexa Therapeutics Future Growth

Future criteria checks 0/6

Ernexa Therapeutics's earnings are forecast to decline at 19.4% per annum. EPS is expected to grow by 65.5% per annum.

Key information

-19.4%

Earnings growth rate

65.49%

EPS growth rate

Biotechs earnings growth25.0%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated08 May 2026

Recent future growth updates

Recent updates

Seeking Alpha • Oct 11

Brooklyn Immunotherapeutics announces name change to Eterna Therapeutics

Brooklyn ImmunoTherapeutics (NASDAQ:BTX) said on Tuesday that it was changing its name to Eterna Therapeutics Inc. to reflect its focus on developing therapies using its patented in-licensed mRNA cell engineering technologies. The name change will be effective Monday, October 17. The company's common stock will trade on the Nasdaq under the new ticker symbol "ERNA". (BTX) has risen ~5%.
Seeking Alpha • Jul 26

Brooklyn ImmunoTherapeutics releases head and neck cancer phase 2 trial results

A phase 2 trial of Brooklyn ImmunoTherapeutics' (NASDAQ:BTX) head and neck cancer candidate IRX-2 showed that the treatment tended to benefit patients more with later stage disease compared to those with earlier stages. The primary endpoint of the study was to estimate 2-year event-free survival (EFS). Secondary endpoints included overall survival and safety. Results showed that at two years of follow-up in the intention-to-treat population, median EFS was 48.3 months. Also, patients who received radiation only (no chemotherapy) as part of adjuvant therapy fared better than those who received both. Adverse events were higher in the treatment arm compared to the control arm. Brooklyn ImmunoTherapeutics (BTX) CEO Matt Angel said the results "provide a clear path forward for testing in patient populations that may benefit from treatment with IRX-2 in combination with checkpoint inhibitors." Brooklyn ImmunoTherapeutics (BTX), which is down ~89% year to date, is viewed as a strong sell by Seeking Alpha's Quant Rating.

Earnings and Revenue Growth Forecasts

NasdaqCM:ERNA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-20N/AN/A1
12/31/2027N/A-13N/AN/A1
12/31/2026N/A-12N/AN/A1
3/31/2026N/A-11-7-7N/A
12/31/2025N/A-14-7-7N/A
9/30/20250-18-9-9N/A
6/30/20250-44-14-14N/A
3/31/20251-46-14-14N/A
12/31/20241-45-16-16N/A
9/30/20241-45-17-17N/A
6/30/20240-24-17-16N/A
3/31/20240-23-18-18N/A
12/31/20230-22-20-20N/A
9/30/20230-20-21-21N/A
6/30/2023N/A-22-22-21N/A
3/31/2023N/A-21-22-22N/A
12/31/2022N/A-25-21-21N/A
9/30/2022N/A-28-23-22N/A
6/30/2022N/A-107-23-23N/A
3/31/2022N/A-113-26-25N/A
12/31/2021N/A-123-24-23N/A
9/30/2021N/A-117-18-18N/A
6/30/2021N/A-33-14-14N/A
3/31/2021N/A-25-10-10N/A
12/31/2020N/A-7-8-8N/A
9/30/2020N/A-8-9-8N/A
6/30/2020N/A-8-8-7N/A
3/31/2020N/A-8-9-8N/A
12/31/2019N/A-9N/A-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ERNA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ERNA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ERNA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ERNA's revenue is forecast to grow faster than the US market.

High Growth Revenue: ERNA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ERNA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/19 14:23
End of Day Share Price 2026/05/19 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ernexa Therapeutics Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Kristen KluskaCantor Fitzgerald & Co.
Jason McCarthyMaxim Group